Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 215561, held by Lupin. Topiramate.
As of Nov 15, 2026, ANDA 215561 (Topiramate), held by Lupin, was first approved by FDA on Jul 11, 2024, with 0 approved supplements and 0 published complete response letters.
Topiramate extended-release capsules USP are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older; adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate extended-release capsules USP are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 11, 2024 | Original application | Approved | None posted |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters